Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
Authors Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M
Received 20 July 2017
Accepted for publication 14 November 2017
Published 29 December 2017 Volume 2018:14 Pages 103—115
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Roger Pinder
Emmanuelle Weiller,1 Catherine Weiss,2 Christopher P Watling,3 Christopher Edge,3 Mary Hobart,2 Hans Eriksson,1 Maurizio Fava4–6
1H. Lundbeck A/S, Valby, Copenhagen, Denmark; 2Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA; 3Cambridge Medical Communication Ltd, Cambridge, UK; 4Division of Clinical Research of the MGH Research Institute, 5Department of Psychiatry, 6Clinical Trials Network & Institute (CTNI), Massachusetts General Hospital, Boston, MA, USA
Objective: Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT.
Methods: This was a systematic literature review of articles in any language from the MEDLINE database published between January 1990 and March 2017. Eligible studies met the following criteria: patients with MDD; inadequate response to at least one ADT; adjunctive therapy (pharmacological or otherwise) to ADT; placebo control group; randomized controlled trial or a post hoc analysis of a randomized controlled trial; reported a self-rated functioning scale. Study characteristics and functioning efficacy data were extracted.
Results: A total of 2,090 discrete records were screened, 293 full-text articles were assessed for eligibility, and 26 studies were included. All studies were acute (6–12 weeks) except for one 52-week study. The only self-rated functioning scale used in the included studies was the Sheehan Disability Scale (SDS). Of the 13 adjunctive agents identified, aripiprazole, brexpiprazole, edivoxetine, and risperidone improved functioning versus placebo (p<0.05), as measured by the SDS total or mean score. On the SDS “work/studies” item, only aripiprazole had a statistically significant benefit, in one study out of four. Thus, where a benefit was observed on the SDS total or mean, this was generally driven by improvement on the “social life” and “family life” items. A limitation of the review is that it only considered published literature from one database.
Conclusion: The SDS, a self-rated functional measure, is informative in acute randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. However, the item that measures work performance may be less relevant to this population than the items that measure social and family life.
Keywords: depression, antidepressant, adjunct, Sheehan Disability Scale, functional, work
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]